Research programme: cytotoxic therapeutics - Supratek

Drug Profile

Research programme: cytotoxic therapeutics - Supratek

Alternative Names: SP 1010C; SP 1010C-O; SP 1050C; SP 1051C; SP 1053C; SP 1060C-O; SP 5.210C

Latest Information Update: 16 Jul 2016

Price : $50

At a glance

  • Originator Supratek Pharma
  • Class Anthracyclines; Camptothecins; Paclitaxels; Taxanes; Tetrahydronaphthalenes
  • Mechanism of Action DNA intercalators; DNA topoisomerase I inhibitors; RNA synthesis inhibitors; Tubulin inhibitors; Tubulin polymerisation inhibitors; Type II DNA topoisomerase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • Available For Licensing Yes

Highest Development Phases

  • No development reported Cancer

Most Recent Events

  • 16 Jul 2016 No recent reports of development identified for preclinical development in Cancer in USA (PO)
  • 28 Nov 2007 Research programme: cytotoxic therapeutics - Supratek is available for licensing as of 28 Nov 2007. http://www.supratek.com
  • 07 Apr 2000 Preclinical development for Cancer in USA (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top